GlassScriptPhysician profile
Mark Layton
NPI 1891846077
$9,626.46
in general payments reported to CMS, 2019-2025
26 companies · $889 in 2025
The $889 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,494 · 2020: $1,433 · 2021: $1,421 · 2022: $1,119 · 2023: $1,117 · 2024: $1,153 · 2025: $889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,124 · Education: $35.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,124.30 |
| Education | $35.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,000.50 | 2019-2025 | Enbrel, Otezla, Otezla |
| Pfizer INC. | $1,376.33 | 2019-2025 | |
| Abbvie INC. | $1,148.19 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,031.03 | 2019-2025 | |
| Janssen Biotech, INC. | $727.68 | 2019-2023 | Simponi, Simponi Aria, Stelara |
| Organon LLC | $212.67 | 2022-2025 | Hadlima, Renflexis |
| Horizon Therapeutics Plc | $151.15 | 2019-2020 | |
| Glaxosmithkline, LLC. | $110.33 | 2019-2022 | |
| Hikma Pharmaceuticals USA | $105.14 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $97.96 | 2022-2025 | Saphnelo |
| Ucb, INC. | $87.56 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $82.88 | 2019 | |
| Genentech USA, INC. | $78.08 | 2019 | |
| Lilly USA, LLC | $73.68 | 2019 | |
| Merck Sharp & Dohme LLC | $43.40 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $42.81 | 2023 | Lupkynis |
| Sebela Pharmaceuticals INC. | $40.16 | 2019 | |
| Celgene Corporation | $38.16 | 2019 | |
| Celltrion USA INC. | $32.67 | 2023-2025 | Vegzelma, Yuflyma |
| Sandoz INC. | $26.71 | 2023 | Hyrimoz |
| Regeneron Healthcare Solutions, INC. | $26.59 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.90 | 2024 | Simlandi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.12 | 2019 | |
| Bioventus LLC | $16.42 | 2019 | |
| Pacira Therapeutics, INC. | $16.32 | 2019 | |
| Fresenius Kabi USA, LLC | $13.02 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Layton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.